The pharmaceutical industry is witnessing a seismic shift, fueled by the meteoric rise of GLP-1 agonist molecules. Once a niche class of diabetes drugs, GLP-1 agonists have become the cornerstone of a global race to conquer obesity, a disease that has more than doubled in prevalence since 1990 and now affects over 42% of U.S. adults and nearly a billion people worldwide. The promise? A shot at transforming pharma giants into trillion-dollar titans and rewriting the future of healthcare.
Obesity has emerged as a major global health crisis, closely associated with a host of chronic conditions such as type 2 diabetes, heart failure, kidney disease, and various cancers...
